Page last updated: 2024-08-17

1,2,3,4-tetrahydroisoquinoline and Experimental Mammary Neoplasms

1,2,3,4-tetrahydroisoquinoline has been researched along with Experimental Mammary Neoplasms in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Lin, X; Luo, G; Ma, L; Ren, S; Wang, X; Wu, S; Xiang, H1

Other Studies

1 other study(ies) available for 1,2,3,4-tetrahydroisoquinoline and Experimental Mammary Neoplasms

ArticleYear
Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
    European journal of medicinal chemistry, 2021, Dec-15, Volume: 226

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Drug Development; Drug Screening Assays, Antitumor; Estrogen Receptor alpha; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Structure-Activity Relationship; Tetrahydroisoquinolines; Tumor Cells, Cultured

2021